Study on Biomarkers of Immune-Related Adverse Events
NCT07527585 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 440
Last updated 2026-04-14
Summary
1. To identify biomarkers of immune-related adverse events;
2. To develop a predictive model for immune-related adverse events.
Conditions
- Immune-Related Adverse Events
Sponsors & Collaborators
-
Huazhong University of Science and Technology
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-30
- Primary Completion
- 2032-12-31
- Completion
- 2032-12-31
More Related Trials
-
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
NCT04871165 ·Status: UNKNOWN
-
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies
NCT02880046 ·Status: UNKNOWN
-
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
NCT04283539 ·Status: RECRUITING
-
ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)
NCT06900296 ·Status: NOT_YET_RECRUITING
-
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582 ·Status: COMPLETED
-
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
NCT04324996 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy
NCT05669638 ·Status: RECRUITING
-
A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)
NCT06756295 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
NCT04408950 ·Status: COMPLETED
-
Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs
NCT03984318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation
NCT04609930 ·Status: COMPLETED
-
Phase II Study of TAEST16001 in Soft Tissue Sarcoma
NCT05549921 ·Status: RECRUITING ·Phase: PHASE2
-
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906 ·Status: UNKNOWN ·Phase: PHASE1
-
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341 ·Status: RECRUITING ·Phase: PHASE1
-
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
NCT06300853 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Immune Signaling Networks in Healthy Human Volunteers
NCT01882582 ·Status: COMPLETED
-
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
NCT04242095 ·Status: RECRUITING
-
T Cell Response in Hypersensitivity Syndrome
NCT00213447 ·Status: COMPLETED
-
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
NCT03778814 ·Status: RECRUITING ·Phase: PHASE1
-
Study of the Anti-tumoral Immune Response
NCT02854644 ·Status: COMPLETED ·Phase: NA
-
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
NCT03047811 ·Status: UNKNOWN ·Phase: NA
-
IMMUNO-FIT Observational Study
NCT07354971 ·Status: RECRUITING
-
Thymosin Alpha-1 for irAE Secondary to ICIs
NCT06178146 ·Status: RECRUITING ·Phase: PHASE4
-
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders
NCT03123458 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
NCT05132855 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2